Skip to Main Content

Author Details

Irene Lui
Department of Pharmaceutical Chemistry, University of California san francisco
2013
19
9
Andrej Sali (CM4AI)
PMIDPaper TitleJournal TitlePublished Year
36805129Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps.Structure2023
37961561Multi-scale photocatalytic proximity labeling reveals cell surface neighbors on and between cells.bioRxiv2023
35027731BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2.Nat Cell Biol2022
36313159Direct Identification of Proteolytic Cleavages on Living Cells Using a Glycan-Tethered Peptide Ligase.ACS Cent Sci2022
35982665Computational pipeline provides mechanistic understanding of Omicron variant of concern neutralizing engineered ACE2 receptor traps.bioRxiv2022
34813293Phage-Based Profiling of Rare Single Cells Using Nanoparticle-Directed Capture.ACS Nano2021
33767397Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection.Nat Biotechnol2021
33536314Mapping proteolytic neo-N termini at the surface of living cells.Proc Natl Acad Sci U S A2021
33666135Bispecific VH/Fab antibodies targeting neutralizing and non-neutralizing Spike epitopes demonstrate enhanced potency against SARS-CoV-2.MAbs2021
33501440BRD2 inhibition blocks SARS-CoV-2 infection by reducing transcription of the host cell receptor ACE2.bioRxiv2021
32511506A SARS-CoV-2 serological assay to determine the presence of blocking antibodies that compete for human ACE2 binding.medRxiv2020
33093202Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.Proc Natl Acad Sci U S A2020
32938700Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.mSphere2020
32766586Engineered ACE2 receptor traps potently neutralize SARS-CoV-2.bioRxiv2020
32839788Engineering luminescent biosensors for point-of-care SARS-CoV-2 antibody detection.medRxiv2020
31694242Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.Antibodies (Basel)2019
33434990Lateral Microscope Enables the Direct Observation of Cellular Interfaces and Quantification of Changes in Cell Morphology during Adhesion.ACS Biomater Sci Eng2016
24185689Mutagenesis modulates the uptake efficiency, cell-selectivity, and functional enzyme delivery of a protein transduction domain.Mol Biosyst2014
23521800A protein transduction domain with cell uptake and selectivity profiles that are controlled by multivalency effects.Chem Biol2013
  • 1 - 19 of 19

Recommended Authors

Ottawa Hospital Research Institute, University of Ottawa
Career Start Year 2018
Number of shared co-authors 1
Stanford University
Career Start Year 2017
Number of shared co-authors 2
KTH - Royal Institute of Technology
Career Start Year 2014
Number of shared co-authors 0
Department of Pharmacological Sciences, Icahn School of Medicine at Mount Sinai
Career Start Year 2014
Number of shared co-authors 1
Ottawa Hospital Research Institute
Career Start Year 2014
Number of shared co-authors 1
The Rockefeller University
Career Start Year 2013
Number of shared co-authors 1
Roche Pharma Research & Early Development (pRED)
Career Start Year 2011
Number of shared co-authors 0
Icahn School of Medicine at Mount Sinai
Career Start Year 2009
Number of shared co-authors 0
Novo Nordisk Research Center Seattle Inc., Inc.
Career Start Year 2008
Number of shared co-authors 0
Yale University School of Medicine
Career Start Year 2006
Number of shared co-authors 2
KTH - Royal Institute of Technology
Career Start Year 2005
Number of shared co-authors 0
Department of Pharmaceutical Chemistry, University of California San Francisco
Career Start Year 2004
Number of shared co-authors 3
University of Massachusetts Chan Medical School
Career Start Year 2003
Number of shared co-authors 1
Stem Cell Translational Research Center of Tongji Hospital, Tongji University
Career Start Year 2000
Number of shared co-authors 0
ETH Zurich
Career Start Year 1998
Number of shared co-authors 1
Pfizer Inc.
Career Start Year 1997
Number of shared co-authors 2
Vanderbilt University Medical Center
Career Start Year 1997
Number of shared co-authors 0
KTH Royal Institute of Technology
Career Start Year 1997
Number of shared co-authors 0
Pfizer Inc.
Career Start Year 1997
Number of shared co-authors 3
Stanford University
Career Start Year 1996
Number of shared co-authors 1
Technical University of Denmark
Career Start Year 1995
Number of shared co-authors 0
Pfizer Inc.
Career Start Year 1994
Number of shared co-authors 3
School of Pharmacy, University of Waterloo
Career Start Year 1993
Number of shared co-authors 2
Northwestern University
Career Start Year 1992
Number of shared co-authors 0
National Institutes of Health, National Center for Advancing Translational Sciences
Career Start Year 1992
Number of shared co-authors 0
Stanford University
Career Start Year 1992
Number of shared co-authors 1
Zhengzhou University
Career Start Year 1992
Number of shared co-authors 0
University of California San Diego
Career Start Year 1990
Number of shared co-authors 0
KTH Royal Institute of Technology
Career Start Year 1990
Number of shared co-authors 0
Rutgers Cancer Institute of New Jersey
Career Start Year 1983
Number of shared co-authors 0

Collaborators

Department of Pharmaceutical Chemistry, University of California San Francisco
Co-authored papers 9
University of California san francisco
Co-authored papers 4
University of California san francisco
Co-authored papers 4
University of California San Francisco
Co-authored papers 2
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 2
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 2
University of California san francisco
Co-authored papers 2
University of California san francisco
Co-authored papers 2
Institute of Immunity, Stanford University School of Medicine
Co-authored papers 2
NYU Grossman School of Medicine
Co-authored papers 2
University of California san francisco
Co-authored papers 2
Synthego Corporation
Co-authored papers 2
University of California, University of California San Francisco
Co-authored papers 2
University of California San Francisco
Co-authored papers 2
Institut Pasteur, Universite Paris Cite, CNRS UMR 9
Co-authored papers 2
University of California san francisco
Co-authored papers 2
University of California san francisco
Co-authored papers 2
Synthego Corporation
Co-authored papers 2
Institute for Neurodegenerative Diseases, University of California san francisco
Co-authored papers 2
University of California san francisco
Co-authored papers 2
Weill Institute for Neurosciences, University of California-San Francisco
Co-authored papers 2
University of California san francisco
Co-authored papers 2
Synthego Corporation
Co-authored papers 2
University of California san francisco
Co-authored papers 2
University of Michigan Medical School ann arbor
Co-authored papers 2
Gladstone Institutes
Co-authored papers 2
Department of Pharmaceutical Chemistry, University of California san francisco
Co-authored papers 2
Quantitative Biosciences Institute (QBI) Coronavirus Research Group (QCRG)
Co-authored papers 2
Washington University School of Medicine
Co-authored papers 2
University of California san francisco
Co-authored papers 2